Your browser doesn't support javascript.
loading
Inducing Persistent Flow Disturbances Accelerates Atherogenesis and Promotes Thin Cap Fibroatheroma Development in D374Y-PCSK9 Hypercholesterolemic Minipigs.
Pedrigi, Ryan M; Poulsen, Christian Bo; Mehta, Vikram V; Ramsing Holm, Niels; Pareek, Nilesh; Post, Anouk L; Kilic, Ismail Dogu; Banya, Winston A S; Dall'Ara, Gianni; Mattesini, Alessio; Bjørklund, Martin M; Andersen, Niels P; Grøndal, Anna K; Petretto, Enrico; Foin, Nicolas; Davies, Justin E; Di Mario, Carlo; Fog Bentzon, Jacob; Erik Bøtker, Hans; Falk, Erling; Krams, Rob; de Silva, Ranil.
Afiliação
  • Pedrigi RM; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Poulsen CB; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Mehta VV; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Ramsing Holm N; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Pareek N; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Post AL; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Kilic ID; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Banya WA; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Dall'Ara G; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Mattesini A; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Bjørklund MM; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Andersen NP; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Grøndal AK; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Petretto E; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Foin N; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Davies JE; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Di Mario C; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Fog Bentzon J; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Erik Bøtker H; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Falk E; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • Krams R; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
  • de Silva R; From Department of Bioengineering, Imperial College London, United Kingdom (R.M.P., V.V.M., A.L.P., R.K.); Institute of Clinical Medicine, Aarhus University Hospital, Denmark (C.B.P., N.R.H., M.M.B., N.P.A., A.K.G., J.F.B., E.F.); Department of Cardiology, Aarhus University Hospital, Denmark (C.B.P.
Circulation ; 132(11): 1003-12, 2015 Sep 15.
Article em En | MEDLINE | ID: mdl-26179404
ABSTRACT

BACKGROUND:

Although disturbed flow is thought to play a central role in the development of advanced coronary atherosclerotic plaques, no causal relationship has been established. We evaluated whether inducing disturbed flow would cause the development of advanced coronary plaques, including thin cap fibroatheroma. METHODS AND

RESULTS:

D374Y-PCSK9 hypercholesterolemic minipigs (n=5) were instrumented with an intracoronary shear-modifying stent (SMS). Frequency-domain optical coherence tomography was obtained at baseline, immediately poststent, 19 weeks, and 34 weeks, and used to compute shear stress metrics of disturbed flow. At 34 weeks, plaque type was assessed within serially collected histological sections and coregistered to the distribution of each shear metric. The SMS caused a flow-limiting stenosis, and blood flow exiting the SMS caused regions of increased shear stress on the outer curvature and large regions of low and multidirectional shear stress on the inner curvature of the vessel. As a result, plaque burden was ≈3-fold higher downstream of the SMS than both upstream of the SMS and in the control artery (P<0.001). Advanced plaques were also primarily observed downstream of the SMS, in locations initially exposed to both low (P<0.002) and multidirectional (P<0.002) shear stress. Thin cap fibroatheroma regions demonstrated significantly lower shear stress that persisted over the duration of the study in comparison with other plaque types (P<0.005).

CONCLUSIONS:

These data support a causal role for lowered and multidirectional shear stress in the initiation of advanced coronary atherosclerotic plaques. Persistently lowered shear stress appears to be the principal flow disturbance needed for the formation of thin cap fibroatheroma.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluxo Sanguíneo Regional / Vasos Coronários / Aterosclerose / Placa Aterosclerótica / Hipercolesterolemia Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Circulation Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluxo Sanguíneo Regional / Vasos Coronários / Aterosclerose / Placa Aterosclerótica / Hipercolesterolemia Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Circulation Ano de publicação: 2015 Tipo de documento: Article